Aberdeen Group’s Ocular Therapeutix OCUL Stock Holding History

Aberdeen Group’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-558,380	Closed	-$4.73M	–	964
2026 Q1	$4.73M	Buy	+558,380	New	+$5.32M	0.01%	696

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aberdeen Group's OCUL Position: Q2 2026 in Review

Aberdeen Group sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 558,380 shares — an estimated $4.73M sold.

Aberdeen Group first reported a position in OCUL in Q1 2026 and held it in 1 quarter. The position peaked at $4.73M in Q1 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Aberdeen Group reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
Aberdeen Group sold 558,380 Ocular Therapeutix shares in Q2 2026, an estimated $4.73M.
Aberdeen Group first reported a position in Ocular Therapeutix in Q1 2026 and held it in 1 quarter.
Aberdeen Group's Ocular Therapeutix position peaked at $4.73M in Q1 2026.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.